Reporte de caso: familia que padece enfermedad de Fabry. Análisis de su expresión clínica
| dc.contributor.author | Coba Lacle, José Antonio | |
| dc.date.accessioned | 2020-02-17T16:30:07Z | |
| dc.date.available | 2020-02-17T16:30:07Z | |
| dc.date.issued | 2019 | |
| dc.description.abstract | La Enfermedad de Fabry forma parte de las enfermedades ligadas a errores innatos del metabolismo, del subgrupo de enfermedades lisosomales; y se caracteriza por la deficiencia de la actividad de la enzima lisosomal llamada a-galactosidasa A (a-Gal A), enzima que interviene en el catabolismo de los glicoesfingolípidos. El defecto enzimático lleva a la acumulación de Globotriaosilceramida (GL-3) y de otros glicoesfingolípidos. Mediante la realización de una encuesta familiar se evaluó grado de autoconocimiento de los otros miembros de la familia que padece FD. Valorando de esta manera logramos estimar su calidad de vida mediante, estrato socioeconómico, nivel de educación, edad, género, profesiones. Además se presentan dos casos clínicos de pacientes que cursan con FD. | spa |
| dc.description.abstract | Fabry's disease is part of the diseases linked to inborn errors of metabolism, of the subgroup of lysosomal diseases; and is characterized by a deficiency in the activity of the lysosomal enzyme called a-galactosidase A (a-Gal A), an enzyme that is involved in the catabolism of glycosphingolipids. The enzyme defect leads to the accumulation of Globotriaosylceramide (GL-3) and other glycosphingolipids. By conducting a family survey, the degree of self-knowledge of the other family members suffering from FD was evaluated. In this way, we estimate their quality of life through socioeconomic status, level of education, age, gender, professions. In addition, there are two clinical cases of patients with FD. | eng |
| dc.format.mimetype | spa | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12442/4756 | |
| dc.language.iso | spa | spa |
| dc.publisher | Ediciones Universidad Simón Bolívar | spa |
| dc.publisher | Facultad de Ciencias Básicas y Biomédicas | spa |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | eng |
| dc.rights.accessrights | info:eu-repo/semantics/restrictedAccess | spa |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.subject | Glicoesfingolípidos | spa |
| dc.subject | Enfermedad lisosomal | spa |
| dc.subject | Alfagalactosidasa | spa |
| dc.subject | Síndrome Fabry Anderson | spa |
| dc.subject | Lisosoma | spa |
| dc.subject | Enfermedad De Fabry | spa |
| dc.subject | Fabry | spa |
| dc.subject | Glycosphingolipids | eng |
| dc.subject | Lysosomal Disease | eng |
| dc.subject | Alphagalactosidase | eng |
| dc.subject | Fabry Anderson Syndrome | eng |
| dc.subject | Lysosome | eng |
| dc.subject | Fabry Disease | eng |
| dc.title | Reporte de caso: familia que padece enfermedad de Fabry. Análisis de su expresión clínica | spa |
| dc.type | Other | spa |
| dc.type.driver | Other | spa |
| dcterms.references | Teresa M, Martino D, Scionti F, Sestito S, Nicoletti A, Arbitrio M, et al. Genetic variants associated with gastrointestinal symptoms in Fabry disease. 2016;7(52):85895–904. z | eng |
| dcterms.references | Martins AM, D’Almeida V, Kyosen SO, Takata ET, Delgado AG, Gonçalves AMBF, et al. Guidelines to diagnosis and monitoring of Fabry disease and review of treatment experiences. J Pediatr. 2009;155(4 Suppl):S19–31. | eng |
| dcterms.references | Toyooka K. Fabry disease [Internet]. 1st ed. Vol. 115, Handbook of Clinical Neurology. Elsevier B.V.; 2013. 629–642 p. Available from: http://dx.doi.org/10.1016/B978-0-444-52902-2.00037-0 | eng |
| dcterms.references | Verstegen RHJ, Theodore M, van de Klerk H, Morava E. Lymphatic edema in congenital disorders of glycosylation. JIMD Rep. 2012;4(18):113–6. | eng |
| dcterms.references | Richter T, Nestler-Parr S, Babela R, Khan ZM, Tesoro T, Molsen E, et al. Rare Disease Terminology and Definitions-A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group. Value Heal [Internet]. 2015;18(6):906–14. Available from: http://dx.doi.org/10.1016/j.jval.2015.05.008 | eng |
| dcterms.references | ENFERMEDADES HUERFANAS cuenta de alto costo colombia - https://cuentadealtocosto.org/site/index.php/patologias/9-patologias/24-enfermedades-huerfanas/?template=cuentadealtocostocontenido. | spa |
| dcterms.references | Schiffmann R, Fuller M, Clarke LA, Aerts JMFG. Is it Fabry disease? Genet Med [Internet]. 2016;(January):1–5. Available from: http://www.nature.com/doifinder/10.1038/gim.2016.55 | eng |
| dcterms.references | The Human Gene Mutation Database - GLA Gene [Internet]. [cited 2019 Feb 13]. Available from: http://www.hgmd.cf.ac.uk/ac/gene.php?gene=GLA | eng |
| dcterms.references | Lidove O, Kaminsky P, Hachulla E, Leguy-Seguin V, Lavigne C, Marie I, et al. Fabry disease “The New Great Imposter”: Results of the French Observatoire in Internal Medicine Departments (FIMeD). Clin Genet. 2012;81(6):571–7. | eng |
| dcterms.references | Schiffmann R, Hughes DA, Linthorst GE, Ortiz A, Svarstad E, Warnock DG, et al. Screening, diagnosis, and management of patients with Fabry disease: conclusions from a “ Kidney Disease: Improving Global Outcomes ” (KDIGO) Controversies Conference. 2017;284–93. | eng |
| dcterms.references | Cammarata G, Fatuzzo P, Rodolico MS, Colomba P, Sicurella L, Iemolo F, et al. High variability of Fabry Disease manifestations in an extended Italian family. Biomed Res Int. 2015;2015(June 2013). | eng |
| dcterms.references | Masson C, Cissé I, Simon V, Insalaco P, Audran M. Fabry disease: A review. Jt Bone Spine. 2004;71(5):381–3. | eng |
| dcterms.references | Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med [Internet]. 2009;11(11):790–6. Available from: http://dx.doi.org/10.1097/GIM.0b013e3181bb05bb | eng |
| dcterms.references | Congreso de Colombia. LEY 1438 DE 2011 [Internet]. [cited 2019 Aug 4]. Available from: http://extwprlegs1.fao.org/docs/pdf/col132763.pdf | spa |
| dcterms.references | Congreso de Colombia. ley 1392 del 2010 [Internet]. [cited 2019 Aug 4]. Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/DIJ/ley-1392-de-2010.pdf | eng |
| dcterms.references | Cantillo J, Rojas W. Enfermedad de Fabry. Med Clin (Barc). 2014;39(2):206–206. | spa |
| dcterms.references | Trujillo NM. Retos de la Investigación en Sistemas y Servicios de Salud. Cienc e Innov en Salud. 2014;2(1):46–51. | spa |
| dcterms.references | Cristina I, Bermeo S. Pacientes En Lista De Trasplante Y Post- Trasplante Renal En Fundación Cardioinfantil. 2015; | spa |
| dcterms.references | RAE. Diccionario de la Real Academia Española - Cromosoma | Definición de cromosoma - Diccionario de la lengua española - Edición del Tricentenario [Internet]. [cited 2019 Feb 13]. Available from: https://dle.rae.es/?id=BLH224E | spa |
| dcterms.references | Griffiths AJ, Miller JH, Suzuki DT, Lewontin RC, Gelbart WM. Sex chromosomes and sex-linked inheritance. W. H. Freeman; 2000. | eng |
| dcterms.references | How many chromosomes do people have? - Genetics Home Reference - NIH [Internet]. [cited 2019 Aug 17]. Available from: https://ghr.nlm.nih.gov/primer/basics/howmanychromosomes | eng |
| dcterms.references | Alliance G, Screening, Services TNY-M-AC for G and N. Genética [Internet]. Genetic Alliance; 2009 [cited 2019 Aug 5]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK132198/ | eng |
| dcterms.references | What are lysosomes? Parts of a cell - Biology - Quatr.us Study Guides [Internet]. [cited 2019 Aug 17]. Available from: https://quatr.us/biology/lysosomes-cell-biology.htm | eng |
| dcterms.references | Cooper GM. Lysosomes. Sinauer Associates; 2000. | eng |
| dcterms.references | Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. The Compartmentalization of Cells. 2002 [cited 2019 Aug 5]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK26907/ | eng |
| dcterms.references | Boustany R-MN. Lysosomal storage diseases--the horizon expands. Nat Rev Neurol [Internet]. 2013;9(10):583–98. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23938739 | eng |
| dcterms.references | Stulnig T. Lysosomale speicherkrankheiten. Austrian J Clin Endocrinol Metab. 2011;4(2):22–6. | eng |
| dcterms.references | Mehta A, Beck M, Sunder-Plassmann G. Fabry Disease [Internet]. Fabry Disease: Perspectives from 5 Years of FOS. Oxford PharmaGenesis; 2006 [cited 2017 Jan 24]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21290683 | eng |
| dcterms.references | Platt FM, Boland B, van der Spoel AC. Lysosomal storage disorders: The cellular impact of lysosomal dysfunction. J Cell Biol. 2012;199(5):723–34. | eng |
| dcterms.references | Giugliani R, Brusius-Facchin A-C, Pasqualim G, Leistner-Segal S, Riegel M, Matte U. Current molecular genetics strategies for the diagnosis of lysosomal storage disorders. Expert Rev Mol Diagn [Internet]. 2016;16(1):113–23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26567866 | eng |
| dcterms.references | GLA gene - Genetics Home Reference - NIH [Internet]. [cited 2019 Aug 5]. Available from: https://ghr.nlm.nih.gov/gene/GLA#location | eng |
| dcterms.references | Fabry Disease - GeneReviews® - NCBI Bookshelf metaanalisis. | eng |
| dcterms.references | Grzeschik KH, Grzeschik AM, Banhof S, Romeo G, Siniscalco M, van Someren H, et al. X-linkage of human -galactosidase. Nat New Biol [Internet]. 1972 Nov 8 [cited 2017 Jan 24];240(97):48–50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/4508394 | eng |
| dcterms.references | Calhoun DH, Bishop DF, Bernstein HS, Quinn M, Hantzopoulos P, Desnick RJ. Fabry disease: isolation of a cDNA clone encoding human alpha-galactosidase A. Proc Natl Acad Sci U S A. 1985;82(November):7364–8. | eng |
| dcterms.references | Bishop DF, Calhoun DH, Bernstein HS, Hantzopoulos P, Quinn M, Desnick RJ. Human alpha-galactosidase A: nucleotide sequence of a cDNA clone encoding the mature enzyme. Proc Natl Acad Sci U S A [Internet]. 1986;83(13):4859–63. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=323842&tool=pmcentrez&rendertype=abstract | eng |
| dcterms.references | Bishop DF, Kornreich R, Desnick RJ. Structural organization of the human alpha-galactosidase A gene: further evidence for the absence of a 3’ untranslated region. Proc Natl Acad Sci U S A. 1988;85(11):3903–7. | eng |
| dcterms.references | Davies JP, Winchester BG, Malcolm S. Sequence variations in the first exon of alpha-galactosidase A. J Med Genet [Internet]. 1993;30(8):658–63. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1016494&tool=pmcentrez&rendertype=abstract | eng |
| dcterms.references | Novo FJ, Kruszewski A, Macdermot KD, Goldspink G, Górecki DC. Editing of human ??-galactosidase RNA resulting in a pyrimidine top purine conversion. Nucleic Acids Res. 1995;23(14):2636–40. | eng |
| dcterms.references | Bernstein HS, Bishop DF, Astrin KH, Kornreich R, Eng CM, Sakuraba H, et al. Fabry disease: six gene rearrangements and an exonic point mutation in the alpha-galactosidase gene. J Clin Invest. 1989;83(21):1390–9. | eng |
| dcterms.references | Matsuzawa F, Aikawa S, Doi H, Okumiya T, Sakuraba H. Fabry disease: correlation between structural changes in alpha-galactosidase, and clinical and biochemical phenotypes. Hum Genet [Internet]. 2005;117(4):317–28. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15924232 | eng |
| dcterms.references | Asociación Colombiana de Medicina Interna. JP, Cantillo J de J. Acta médica colombiana : AMC : órgano de la Asociación Colombiana de Medicina Interna. [Internet]. Vol. 34, Acta Medica Colombiana. Asociación Colombiana de Medicina Interna; 2009 [cited 2019 Aug 17]. 140–151 p. Available from: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-24482009000300009 | spa |
| dcterms.references | ANDERSON W. a Case of “Angeio‐Keratoma.” Br J Dermatol. 1898;10(4):113–7. | eng |
| dcterms.references | Fabry J. Ein Beitrag zur Kenntniss der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae) [A contribution to knowledge on the purpura haemorrhagica nodularis (purpura papulosa haemorrhagica Hebrae)]. Arch Dermatol Syph. 1898;43(1):187–200. | eng |
| dcterms.references | Fabry H, Mehta AB, Beck M (Michael), Sunder-Plassmann G. Fabry disease : perspectives from 5 years of FOS. PharmaGenesis; 2006. 423 p. | eng |
| dcterms.references | Uribe A, Mateus HE, Prieto JC, Palacios MF, Ospina SY, Pasqualim G, et al. Identification of mutations in Colombian patients affected with Fabry disease. Gene [Internet]. 2015;574(2):325–9. Available from: http://dx.doi.org/10.1016/j.gene.2015.08.018 | eng |
| dcterms.references | Eng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO, et al. Fabry disease: Baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis. 2007;30(2):184–92. | eng |
| dcterms.references | Laney D a, Peck DS, Atherton AM, Manwaring LP, Christensen KM, Shankar SP, et al. Fabry disease in infancy and early childhood: a systematic literature review. Genet Med [Internet]. 2014;17(August):1–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25232851 | eng |
| dcterms.references | Laney DA, Bennett RL, Clarke V, Fox A, Hopkin RJ, Johnson J, et al. Fabry disease practice guidelines: Recommendations of the national society of genetic counselors. J Genet Couns. 2013;22(5):555–64. | eng |
| dcterms.references | R ED, Gomaa H, Rp C, Se C, Bazan R, Barretti P, et al. Enzyme replacement therapy for Anderson-Fabry disease ( Review ). 2016;(7). | eng |
| dcterms.references | Hernberg-Ståhl E. Organization and technical aspects of FOS – the Fabry Outcome Survey [Internet]. Fabry Disease: Perspectives from 5 Years of FOS. Oxford PharmaGenesis; 2006 [cited 2017 Jan 26]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21290693 | eng |
| dcterms.references | Beck M. Demographics of FOS – the Fabry Outcome Survey [Internet]. Fabry Disease: Perspectives from 5 Years of FOS. Oxford PharmaGenesis; 2006 [cited 2017 Jan 25]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21290679 | eng |
| dcterms.references | NCBI Protein Database. Alpha-galactosidase [Pseudopedobacter saltans DSM 12145] - Protein - NCBI [Internet]. [cited 2019 Aug 5]. Available from: https://www.ncbi.nlm.nih.gov/protein/ADY53117.1 | eng |
| dcterms.references | Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic Defect in Fabry’s Disease. N Engl J Med [Internet]. 1967 May 25;276(21):1163–7. Available from: http://dx.doi.org/10.1056/NEJM196705252762101 | eng |
| dcterms.references | Smith M. Fabry ’ s Disease : Alpha-Galactosidase Deficiency. 167:5–6. | eng |
| dcterms.references | Winchester B, Young E. Biochemical and genetic diagnosis of Fabry disease [Internet]. Fabry Disease: Perspectives from 5 Years of FOS. Oxford PharmaGenesis; 2006 [cited 2017 Jan 28]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21290697 | eng |
| dcterms.references | Wang AM, Desnick RJ. Structural organization and complete sequence of the human alpha-N-acetylgalactosaminidase gene: homology with the alpha-galactosidase A gene provides evidence for evolution from a common ancestral gene. Genomics [Internet]. 1991 May [cited 2017 Jan 28];10(1):133–42. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1646157 | eng |
| dcterms.references | Lemansky P, Bishop DF, Desnick RJ, Hasilik A, von Figura K. Synthesis and processing of alpha-galactosidase A in human fibroblasts. Evidence for different mutations in Fabry disease. J Biol Chem [Internet]. 1987 Feb 15 [cited 2017 Jan 28];262(5):2062–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3029062 | eng |
| dcterms.references | Kiharali H, Serizawas S, Lis Y. DEFICIENCY IN URINE OF PATIENTS AFFECTED WITH CEREBROSIDE SULFATASE Bio : 1985;260(3):1867–71. | eng |
| dcterms.references | Schiffmann R, Kopp JB, Austin HA, Sabnis S, Moore DF, Weibel T, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA [Internet]. 2001 Jun 6 [cited 2017 Jan 29];285(21):2743–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11386930 | eng |
| dcterms.references | Biegstraaten M, Arngrímsson R, Barbey F, Boks L, Cecchi F, Deegan PB, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis [Internet]. 2015;10:36. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4383065&tool=pmcentrez&rendertype=abstract | eng |
| dcterms.references | Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry’s Disease. N Engl J Med [Internet]. 2001 Jul 5 [cited 2017 Jan 29];345(1):9–16. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11439963 | eng |
| dcterms.references | Hoffmann BB. Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring. Orphanet J Rare Dis. 2009;4:21. | eng |
| dcterms.references | Calzada C, De F, Madroñero M, Pascual Gómez-Moreno I, Tutora I, Belén :, et al. ENFERMEDAD DE FABRY: REVISIÓN BIBLIOGRÁFICA Y ESTUDIO DE UTILIZACIÓN. | spa |
| dcterms.references | Spada M, Kasper D, Pagliardini V, Biamino E, Giachero S, Porta F. Metabolic progression to clinical phenotype in classic Fabry disease. Ital J Pediatr [Internet]. 2017;10–2. Available from: http://dx.doi.org/10.1186/s13052-016-0320-1 | eng |
| dcterms.references | Mehta A, Widmer U. Natural history of Fabry disease [Internet]. Fabry Disease: Perspectives from 5 Years of FOS. Oxford PharmaGenesis; 2006 [cited 2017 Jan 29]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21290671 | eng |
| dcterms.references | Diagnóstico de la enfermedad de fabry - Cardiopatias Familiares [Internet]. [cited 2019 Aug 17]. Available from: http://cardiopatiasfamiliares.es/diagnostico-la-enfermedad-fabry/ | eng |
| dcterms.references | Hoffmann B, Schwarz M, Mehta A, Keshav S. Gastrointestinal Symptoms in 342 Patients With Fabry Disease: Prevalence and Response to Enzyme Replacement Therapy. Clin Gastroenterol Hepatol. 2007;5(12):1447–53. | eng |
| dcterms.references | Sodi A, Ioannidis AS, Mehta A, Davey C, Beck M, Pitz S. Ocular manifestations of Fabry’s disease: Data from the Fabry Outcome Survey. Br J Ophthalmol. 2007;91(2):210–4. | eng |
| dcterms.references | Cornea verticillata [Internet]. [cited 2019 Aug 17]. Available from: https://webeye.ophth.uiowa.edu/eyeforum/atlas/pages/Verticillata/index.htm | eng |
| dcterms.references | Ramaswami U. Update on role of agalsidase alfa in management of Fabry disease. Drug Des Devel Ther. 2011;(5):155–73. | eng |
| dcterms.references | Echevarria L, Benistan K, Toussaint A, Dubourg O, Hagege AA, Eladari D, et al. X-chromosome inactivation in female patients with Fabry disease. Clin Genet. 2016;89(1):44–54. | eng |
| dcterms.references | Cairns T, Müntze J, Gernert J, Spingler L, Nordbeck P, Wanner C. Hot topics in Fabry disease. Postgrad Med J [Internet]. 2018;postgradmedj-2018-136056. Available from: http://pmj.bmj.com/lookup/doi/10.1136/postgradmedj-2018-136056 | eng |
| dcterms.references | García-Trabanino R, Badilla-Porras R, Carazo K, Courville K, de Luna E, Lemus P, et al. Consenso del Grupo Centroamericano y del Caribe para el Estudio y Tratamiento de la Enfermedad de Fabry. Nefrol Latinoam [Internet]. 2017 Jan 1 [cited 2019 Aug 7];14(1):27–38. Available from: https://www.sciencedirect.com/science/article/pii/S2444903216300038 | eng |
| dcterms.references | CHMP. ANEXO I FICHA TÉCNICA O RESUMEN DE LAS CARACTERÍSTICAS DEL PRODUCTO [Internet]. [cited 2019 Aug 17]. Available from: https://www.ema.europa.eu/en/documents/product-information/replagal-epar-product-information_es.pdf | spa |
| dcterms.references | Smid BE, Van Der Tol L, Cecchi F, Elliott PM, Hughes DA, Linthorst GE, et al. Uncertain diagnosis of Fabry disease: Consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance. Int J Cardiol [Internet]. 2014;177(2):400–8. Available from: http://dx.doi.org/10.1016/j.ijcard.2014.09.001 | eng |
| dcterms.references | Keating GM, Simpson D. A Review of its Use in the Management of Fabry Disease. Drugs. 2007;67(3):435–55. | eng |
| dcterms.references | (EMA) EMA. Cetuximab; Erbitux®. Anexo I: Ficha técnica o resumen de las características del producto. Agencia Eur Medicam [Internet]. 2014;1–33. Available from: ec.europa.eu/health/documents/community.../anx_130850_es.pdf | spa |
| dcterms.references | Martín AL. Presentación de la guía 2018 [Internet]. [cited 2019 Feb 14]. Available from: https://www.svneurologia.org/wordpress/wp-content/uploads/2018/03/Guía-ictus-isquemico-agudo-2018.pdf | spa |
| dcterms.references | País N. GUÍA DE PRÁCTICA CLÍNICA DE DIAGNÓSTICO, TRATAMIENTO Y REHABILITACIÓN DEL EPISODIO AGUDO DE ATAQUE CEREBROVASCULAR ISQUÉMICO, EN POBLACIÓN MAYOR DE 18 AÑOS [Internet]. 2015 [cited 2019 Feb 14]. Available from: http://gpc.minsalud.gov.co/gpc_sites/Repositorio/Conv_637/GPC_acv/GPC_ACV_Version_Final_Completa.pdf | spa |
| dcterms.references | Guía de práctica clínica Hipertensión arterial primaria (hta) 2013-Guía No. 18 [Internet]. [cited 2019 Feb 14]. Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/INEC/IETS/GPC_Completa_HTA.pdf | spa |
| dcterms.references | efectos de la suspension de IECA y ARAII en enfermedad renal cronica avanzada. [cited 2019 Feb 14]; Available from: http://www.revistanefrologia.com/es-pdf-X0211699512001160 | spa |
| dcterms.references | Lewis JRP, Gibson PH. Bilateral hip replacement in three patients with lysosomal storage disease: Mucopolysaccharidosis type IV and Mucolipidosis type III. J Bone Jt Surg [Br] [Internet]. 2010 [cited 2019 Aug 14];92(2):92–289. Available from: https://online.boneandjoint.org.uk/doi/pdf/10.1302/0301-620X.92B2.23104 | eng |
| dcterms.references | Selthofer-Relatic K. Case Report Time of Anderson-Fabry Disease Detection and Cardiovascular Presentation. 2018; Available from: https://doi.org/10.1155/2018/6131083 | eng |
| dcterms.references | El Dib R, Gomaa H, Carvalho RP, Camargo SE, Bazan R, Barretti P, et al. Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev. 2016;2016(7). | eng |
| dcterms.references | Zhou C, Huang J, Cui G, Zeng H, Wen Wang D, Zhou Q. Identification of a novel loss-of-function mutation of the GLA gene in a Chinese Han family with Fabry disease. Available from: https://doi.org/10.1186/s12881-018-0734-2 | eng |
| dcterms.references | Liao HC, Hsu TR, Young L, Chiang CC, Huang CK, Liu HC, et al. Functional and biological studies of α-galactosidase A variants with uncertain significance from newborn screening in Taiwan. Mol Genet Metab. 2018 Feb 1;123(2):140–7 | eng |
| dcterms.references | Lavalle L, Thomas AS, Beaton B, Ebrahim H, Reed M, Ramaswami U, et al. Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation. PLoS One. 2018 Apr 1;13(4). | eng |
| oaire.version | info:eu-repo/semantics/acceptedVersion | spa |
| sb.programa | Maestría en Genética | spa |
| sb.sede | Sede Barranquilla | spa |